Dr. Scot Gottlieb on Novo Nodrisk's oral diabetes drug, future of weight-loss drugs
Former FDA Commissioner Dr. Scot Gottlieb joins 'Squawk Box' to discuss news of Novo Nordisk's oral diabetes drug cutting heart-related risks in patients, state of the weight-loss drugs market, and more.
▶︎
A Neuroscientist Breaks Down GLP–1s, Genetics & the Real Science of Fat Loss | Zachary A. Knight
▶︎
Forget Zepbound: 15 New Obesity Drugs Are Coming
▶︎
CEO DIALOGUE #35 - Lars Fruergaard Jørgensen, Novo Nordisk
▶︎
The high cost of 'Instagram face'
▶︎
France vs. England Highlights FIFA World Cup 2026 | Sportschau
▶︎
Watch his reaction when he’s told he’s a GOOD BOY for the first time 🥹
▶︎
'He's Weak': Tucker Carlson on How Trump Failed America | The Mishal Husain Show
▶︎
7 Things You Must NEVER Do on Ozempic or Wegovy (Or It STOPS Working)
▶︎
Ozempic & Mounjaro: Same Shot. Opposite Results.
▶︎
The Novo Nordisk scientist behind Ozempic, Wegovy weight loss research
▶︎
Novo Nordisk CEO on Catalent, Ozempic and Wegovy
▶︎
Why Ancient Humans Went From Black to White?
▶︎
I Investigated The Country Where it's Illegal To Be Fat
▶︎
Warren Buffett: Ended Gates donations to give more to my children, not because of Epstein ties
▶︎
Frankreich – England Highlights | Spiel um Platz 3, FIFA WM 2026 | sportstudio
▶︎
US denies hitting Iranian infrastructure in new wave of strikes | BBC News
▶︎
Peptide Expert: What Do Peptides Actually Do? (EXPLAINED) - Dr Alex Tatem
▶︎
I’m a Pathologist: The "Biological Cost" of Ozempic and Mounjaro.
▶︎
New GLP-1 Pills Are Coming, & Wegovy May Become an Implant!
▶︎